• Peregrine Pharmaceuticals Inc., of Tustin, Calif., said it reached an agreement with the FDA on the design of a single registration trial testing Cotara in patients with recurrent glioblastoma multiforme.
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5423
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST